709 Trial in progress: product characteristics and clinical trial design for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy for solid tumors

Abstract

BackgroundCheckpoint immunotherapies have revolutionized solid tumor treatment yet durably benefit a minority of patients, as they rely on endogenous anti-tumor T cells. A potential solution for patients lacking functional endogenous...